Very low density lipoprotein receptor subtype II silencing by RNA interference inhibits cell proliferation in hepatoma cell lines

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 882-890

  Luo, Min ^a   Liu, Yong Jian ^b   Xia, Li Min ^a   Yan, Wei ^a   Zhu, Qian ^a   Tian, De An ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cell cycle; Cell proliferation; Hepatocellular carcinoma; RNA interference; VLDLR

Indexed keywords

CYCLIN D1; SHORT HAIRPIN RNA; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; GENE SILENCING; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; HEP G2 CELLS; HUMANS; LIPOPROTEINS, VLDL; LIVER NEOPLASMS; OXYGENASES; RECEPTORS, LDL; RNA INTERFERENCE; RNA, MESSENGER;

EID: 78149270904     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chen WJ, Goldstein JL, Brown MS: NPXY, a sequence often found in cytoplasmic tails, is required for coated pitmediated internalization of the low density lipoprotein receptor. J Biol Chem 1990;265:3116-3123.
2. Iijima H, Miyazawa M, Sakai J, Magoori K, Ito MR, Suzuki H, Nose M, Kawarabayasi Y, Yamamoto TT: Expression and characterization of a very low density lipoprotein receptor variant lacking the O-linked sugar region generated by alternative splicing. J Biochem 1998;124:747-755.
3. Webb JC, Patel DD, Jones MD, Knight BL, Soutar AK: Characterization and tissue-specific expression of the human very low density lipoprotein (VLDL) receptor' mRNA. Hum Mol Gene 1994;.3: 531-537.
4. May P, Bock HH, Nimpf J, Herz J: Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. J Biol Chem 2003; 278:37386-37392. (Pubitemid 37175257)
5. Chen T, Wu F, Chen FM, Tian J, Qu S: Variations of very low-density lipoprotein receptor subtype expression in gastrointestinal adenocarcinoma cells with various differentiations. World J Gastroenterol 2005; 11:2817-2821.
6. Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S, Hirohashi S, Inazawa J: Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis Oncogene 2006; 25:6554-6562.
7. Webb DJ, Nguyen DH, Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. J Cell Sci 2000;113:123-134.
8. Martensen PM, Oka K, Christensen L, Rettenberger PM, Petersen HH, Christensen A, Chan L, Heegaard CW, Andreasen PA: Breast carcinoma epithelial cells express a very low-density lipoprotein receptor variant lacking the O-linked glycosylation domain encoded by exon 16, but with full binding activity for serine proteinase/serpin complexes and Mr-40,000 receptor-associated protein. Eur J Biochem 1997;248:583-591.
9. Argraves KM, Battey FD, MacCalman CD, McCrae KR, Gåfvels M, Kozarsky KF, Chappell DA, Strauss JF 3rd, Strickland DK: The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem 1995; 270:26550-26557.
10. Heegaard CW, Simonsen AC, Oka K, Kjøller L, Christensen A, Madsen B, Ellgaard L, Chan L, Andreasen PA: Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J Biol Chem 1995; 270:20855-20861.
11. Webb DJ, Nguyen DH, Sankovic M, Gonias SL: The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J Biol Chem 1999; 274:7412-7420. (Pubitemid 29140560)
12. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS: Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 2004; 103:3374-3380.
13. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK: Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001;276:12241-12248.
14. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka H, Takahashi H, Oyanagi K, Mizusawa H, Kanazawa I, Tsuji S: Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 1995; 11:207-209.
15. Christie RH, Chung H, Rebeck GW, Strickland D, Hyman BT: Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55:491-498.
16. Frykman PK, Brown MS, Yamamoto T, Goldstein JL, Herz J: Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc Natl Acad Sci USA 1995; 92:8453-8457.
17. Nakamura Y, Yamamoto M, Kumamaru E: Very low-density lipoprotein receptor in fetal intestine and gastric adenocarcinoma cells. Arch Pathol Lab Med 2000;124:119-122.
18. Sakai J, Hoshino A, Takahashi S, Miura Y, Ishii H, Suzuki H, Kawarabayasi Y, Yamamoto T: Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 1994; 269(3):2173-2182.
19. Kozarsky KF, Jooss K, Donahee M, Strauss JF 3rd, Wilson JM: Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13:54-62. (Pubitemid 26139294)
20. Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao G, Wilson JM: Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adenoassociated viral vector expressing very-low-density lipoprotein receptor. Mol Ther 2000; 2:256-261.
21. Goudriaan JR, Espirito Santo SM, Voshol PJ, Teusink B, van Dijk KW, van Vlijmen BJ, Romijn JA, Havekes LM, Rensen PC: The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis.J Lipid Res 2004; 45:1475-1481.
22. MacDougall ED, Kramer F, Polinsky P, Barnhart S, Askari B, Johansson F, Varon R, Rosenfeld ME, Oka K, Chan L, Schwartz SM, Bornfeldt KE: Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice. Am J Pathol 2006;168:2064-2073.
23. Hermann M, Mahon MG, Lindstedt KA, Nimpf J, Schneider WJ: Lipoprotein receptors in extraembryonic tissues of the chicken. J Biol Chem 2000; 275(22):16837-16844. (Pubitemid 30398918)
24. Elkin RG, Zhong Y: Assessment of reproductive function in mutant restricted ovulator carrier roosters. Poult Sci 2002; 81:1280-1282.
25. Bujo H, Hermann M, Kaderli MO, Jacobsen L, Sugawara S, Nimpf J, Yamamoto T, Schneider WJ: Chicken oocyte growth is mediated by an eight ligand binding repeat member of the LDL receptor family. EMBO J 1994;13:5165-5175.
26. Carrière M, Rosenberg AR, Conti F, Chouzenoux S, Terris B, Sogni P, Soubrane O, Calmus Y, Podevin P: Low density lipoprotein receptor transcripts correlates with liver hepatitis C virus RNA in patients with alcohol consumption. J Viral Hepat 2006; 13:633-642.
27. Nahmias Y, Casali M, Barbe L, Berthiaume F, Yarmush ML: Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. Hepatology 2006; 43:257-265.
28. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M: Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 2006;130:548-565. (Pubitemid 43202051)